Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Second Quarter and Six-Month Revenue Results
- Year-over-year unaudited revenue increased 114% for the fiscal second quarter and 337% for the six months ended December 31, 2023
- Approximate unaudited revenue of $1.56 million for the six months ended December 31, 2023, representing a significant increase of 337%
- 30% rise in cartridge sales and a 91% rise in reader sales for the six months ended December 31, 2023
- Expansion into new markets and global footprint contributing to revenue growth
- Plans for further market expansion throughout Asia-Pacific in 2024
- None.
Insights
The reported increase in unaudited revenue by Intelligent Bio Solutions Inc. is a significant indicator of the company's growth and market penetration. A 337% rise in six-month revenue and a 114% rise in the second quarter are exceptional figures that far exceed average industry growth rates. Investors will be interested in the sustainability of this growth, considering the company's expansion into new markets such as New Zealand and the anticipated expansion into the Asia-Pacific region.
It's important to note that these preliminary figures are subject to adjustments. Investors should look for consistent growth patterns and the company's ability to maintain margins while scaling up operations. The increase in cartridge and reader sales by 30% and 91% respectively suggests a successful product adoption and an expanding customer base, which could lead to recurring revenue streams. However, investors should also consider the costs associated with market expansion and product development when evaluating the company's long-term profitability.
The drug screening market has been growing due to increased regulatory requirements and a general trend towards workplace safety and productivity. The growing awareness of Intelligent Bio Solutions' drug screening solution and its non-invasive testing technology aligns with current market demands for efficient and cost-effective drug testing methods. The company's strategic market expansion and product sales growth are indicative of its competitive positioning.
Understanding the market dynamics, including the regulatory environment, competitor landscape and customer preferences, is crucial. The company's ability to innovate and adapt to these factors will likely be a determinant of its market share and revenue growth in the future. The expansion into the Asia-Pacific region is particularly notable, as this market has a high growth potential due to its large population and increasing healthcare expenditures.
Intelligent Bio Solutions' focus on rapid, non-invasive testing solutions positions it well within the medical technology sector, which is increasingly moving towards patient-friendly and cost-effective diagnostic methods. The reported sales growth in both cartridges and readers indicates successful product scaling and an effective sales strategy. The company's performance needs to be evaluated against industry benchmarks for similar product launches and market entries.
Furthermore, the company's anticipation of continued revenue growth throughout 2024 suggests confidence in their product pipeline and market strategy. However, it is essential for stakeholders to monitor the company's investment in research and development, as well as its ability to navigate the complex regulatory landscapes, especially with its international market expansions. These factors are critical for maintaining innovation and ensuring long-term success in the medical technology industry.
- Year-over-year unaudited revenue increased
NEW YORK, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for fiscal Second Quarter and six months ended December 31, 2023. The Company expects approximate unaudited revenue of
Spiro Sakiris, Chief Financial Officer at Intelligent Bio Solutions, commented, “Our Q2 and six-month results are very encouraging, showing strong growth compared to 2022 as we continued our focus on penetrating target markets.”
INBS further expects a
"Our product sales are steadily on the rise due to a growing awareness of our drug screening solution, entry into new markets and expansion of our global footprint. Last year, we expanded into New Zealand, and we anticipate further market expansion throughout Asia-Pacific this year,” said Harry Simeonidis, President and Chief Executive Officer at Intelligent Bio Solutions. “Our revenue growth numbers are indicative of an increasing need for an efficient drug screening solution that reduces risk, saves costs, and promotes productivity. We aim to maintain this upward trajectory throughout 2024.”
The preliminary unaudited revenue results for the fiscal second quarter and the six months ended December 31, 2023, are based on information available to management as of the date of this press release and are, therefore, subject to adjustments based on the Company’s completion of its quarter-end financial close process. The Company expects to disclose financial results for the fiscal second quarter and six months ended December 31, 2023, in its upcoming Quarterly Report on Form 10-Q, expected to be filed with the Securities and Exchange Commission during the week commencing February 5, 2024.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company's biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company's current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including" believes,"" estimates,"" anticipates,"" expects,"" plans,"" projects,"" intends,"" potential,"" may,"" could,"" might,"" will,"" should,"" approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Media Contact:
Cheryl Billson
Comma Communications
cheryl.billson@commacomms.com
+44 (0)7791 720460
FAQ
What is the ticker symbol for Intelligent Bio Solutions Inc.?
What is the unaudited revenue increase for the fiscal second quarter?
What is the unaudited revenue for the six months ended December 31, 2023?
What is the expected rise in cartridge sales for the six months ended December 31, 2023?
What is the expected rise in reader sales for the six months ended December 31, 2023?
What are the expansion plans of Intelligent Bio Solutions Inc.?
